Twist Bioscience (NASDAQ:TWST) Posts Earnings Results, Beats Expectations By $0.07 EPS

Key Points

• Twist Bioscience reported an EPS of ($0.47), exceeding analyst expectations by $0.07 as they had anticipated ($0.54).
• The company faces financial challenges with a negative net margin of 54.98% and a negative return on equity of 33.48%.
• Insider trading reports show both the CFO and CEO selling shares, with insider ownership now at 3.01% of the company.

Twist Bioscience (NASDAQ:TWST - Get Free Report) released its earnings results on Monday. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07, Zacks reports. Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. Twist Bioscience updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Twist Bioscience Stock Up 0.3%

Twist Bioscience stock opened at $33.68 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. The firm has a market cap of $2.02 billion, a PE ratio of -10.36 and a beta of 2.37. Twist Bioscience has a twelve month low of $27.12 and a twelve month high of $55.33. The firm's 50 day moving average price is $34.67 and its two-hundred day moving average price is $38.70.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,678 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the sale, the chief executive officer directly owned 645,782 shares of the company's stock, valued at $23,093,164.32. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,109 shares of company stock valued at $425,962 over the last ninety days. Corporate insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. Intech Investment Management LLC grew its position in Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after acquiring an additional 4,591 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company's stock worth $1,585,000 after buying an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company's stock worth $2,765,000 after buying an additional 3,181 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock worth $36,629,000 after buying an additional 37,577 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TWST. Robert W. Baird cut their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Barclays cut their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group cut their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Guggenheim restated a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.